Benzimidazole-2-one: a Novel Anchoring Principle for Antagonizing P53-Mdm2

Overview

Journal Bioorg Med Chem

Specialties Biochemistry
Chemistry

Date 2012 Jul 14

PMID 22789708

Citations 5

Authors

Wei Wang

Haiping Cao

Siglinde Wolf

Miguel S Camacho-Horvitz

Tad A Holak

Alexander Domling

Affiliations

Soon will be listed here.

Abstract

Herein we propose the benzimidazole-2-one substructure as a suitable tryptophan mimic and thus a reasonable starting point for the design of p53 Mdm2 antagonists. We devise a short multicomponent reaction route to hitherto unknown 2-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)acetamides by reacting mono N-carbamate protected phenylenediamine in a Ugi-3CR followed by base induced cyclisation. Our preliminary synthesis and screening results are presented here. The finding of the benzimidazolone moiety as a tryptophan replacement in mdm2 is significant as it offers access to novel scaffolds with potentially higher selectivity and potency and improved biological activities. Observing low μM affinities to mdm2 by NMR and fluorescence polarization we conclude that the 2-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)acetamide scaffold might be a good starting point to further optimize the affinities to Mdm2.

Citing Articles

Rational drug design, synthesis, and biological evaluation of novel chiral tetrahydronaphthalene-fused spirooxindole as MDM2-CDK4 dual inhibitor against glioblastoma.

Wang B, Peng F, Huang W, Zhou J, Zhang N, Sheng J Acta Pharm Sin B. 2020; 10(8):1492-1510.

PMID: 32963945 PMC: 7488488. DOI: 10.1016/j.apsb.2019.12.013.

Artificial Macrocycles.

Abdelraheem E, Shaabani S, Domling A Synlett. 2019; 29(9):1136-1151.

PMID: 31354188 PMC: 6660156. DOI: 10.1055/s-0036-1591975.

Scaffold hopping via ANCHOR.QUERY: β-lactams as potent p53-MDM2 antagonists.

Shaabani S, Neochoritis C, Twarda-Clapa A, Musielak B, Holak T, Domling A Medchemcomm. 2017; 8(5):1046-1052.

PMID: 29034069 PMC: 5637554. DOI: 10.1039/C7MD00058H.

Discovery of a Potent Allosteric Kinase Modulator by Combining Computational and Synthetic Methods.

Kroon E, Schulze J, Suss E, Camacho C, Biondi R, Domling A Angew Chem Int Ed Engl. 2015; 54(47):13933-6.

PMID: 26385475 PMC: 4721676. DOI: 10.1002/anie.201506310.

Multicomponent reactions for de novo synthesis of BODIPY probes: in vivo imaging of phagocytic macrophages.

Vazquez-Romero A, Kielland N, Arevalo M, Preciado S, Mellanby R, Feng Y J Am Chem Soc. 2013; 135(43):16018-21.

PMID: 24111937 PMC: 6168057. DOI: 10.1021/ja408093p.

References

Baell J, Holloway G . New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem. 2010; 53(7):2719-40. DOI: 10.1021/jm901137j. View

Bissantz C, Kuhn B, Stahl M . A medicinal chemist's guide to molecular interactions. J Med Chem. 2010; 53(14):5061-84. PMC: 2905122. DOI: 10.1021/jm100112j. View

Kussie P, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine A . Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science. 1996; 274(5289):948-53. DOI: 10.1126/science.274.5289.948. View

Salum L, Valadares N . Fragment-guided approach to incorporating structural information into a CoMFA study: BACE-1 as an example. J Comput Aided Mol Des. 2010; 24(10):803-17. DOI: 10.1007/s10822-010-9375-z. View

Vassilev L, Vu B, Graves B, Carvajal D, Podlaski F, Filipovic Z . In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004; 303(5659):844-8. DOI: 10.1126/science.1092472. View

Khoury K, Popowicz G, Holak T, Domling A . The p53-MDM2/MDMX axis - A chemotype perspective. Medchemcomm. 2014; 2:246-260. PMC: 3898590. DOI: 10.1039/C0MD00248H. View

Popowicz G, Czarna A, Rothweiler U, Szwagierczak A, Krajewski M, Weber L . Molecular basis for the inhibition of p53 by Mdmx. Cell Cycle. 2007; 6(19):2386-92. DOI: 10.4161/cc.6.19.4740. View

Tanaka Y, Hasui T, Suginome M . Acid-free, aminoborane-mediated Ugi-type reaction leading to general utilization of secondary amines. Org Lett. 2007; 9(22):4407-10. DOI: 10.1021/ol701570c. View

Popowicz G, Domling A, Holak T . The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious. Angew Chem Int Ed Engl. 2011; 50(12):2680-8. PMC: 3113661. DOI: 10.1002/anie.201003863. View

10.

Huggins D, Sherman W, Tidor B . Rational approaches to improving selectivity in drug design. J Med Chem. 2012; 55(4):1424-44. PMC: 3285144. DOI: 10.1021/jm2010332. View

11.

Krajewski M, Ozdowy P, DSilva L, Rothweiler U, Holak T . NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro. Nat Med. 2005; 11(11):1135-6. DOI: 10.1038/nm1105-1135. View

12.

Popowicz G, Czarna A, Wolf S, Wang K, Wang W, Domling A . Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery. Cell Cycle. 2010; 9(6):1104-11. DOI: 10.4161/cc.9.6.10956. View

13.

Cheok C, Verma C, Baselga J, Lane D . Translating p53 into the clinic. Nat Rev Clin Oncol. 2010; 8(1):25-37. DOI: 10.1038/nrclinonc.2010.174. View

14.

Rehm T, Huber R, Holak T . Application of NMR in structural proteomics: screening for proteins amenable to structural analysis. Structure. 2002; 10(12):1613-8. DOI: 10.1016/s0969-2126(02)00894-8. View

15.

Grasberger B, Lu T, Schubert C, Parks D, Carver T, Koblish H . Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J Med Chem. 2005; 48(4):909-12. DOI: 10.1021/jm049137g. View

16.

Zou B, Yuan Q, Ma D . Cascade coupling/cyclization process to N-substituted 1,3-dihydrobenzimidazol-2-ones. Org Lett. 2007; 9(21):4291-4. DOI: 10.1021/ol701792j. View

17.

Popowicz G, Czarna A, Holak T . Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain. Cell Cycle. 2008; 7(15):2441-3. DOI: 10.4161/cc.6365. View

18.

Huang Y, Wolf S, Koes D, Popowicz G, Camacho C, Holak T . Exhaustive fluorine scanning toward potent p53-Mdm2 antagonists. ChemMedChem. 2011; 7(1):49-52. PMC: 3772510. DOI: 10.1002/cmdc.201100428. View

19.

Dong X, Jiang C, Hu H, Yan J, Chen J, Hu Y . QSAR study of Akt/protein kinase B (PKB) inhibitors using support vector machine. Eur J Med Chem. 2009; 44(10):4090-7. DOI: 10.1016/j.ejmech.2009.04.050. View

20.

Fry D, Emerson S, Palme S, Vu B, Liu C, Podlaski F . NMR structure of a complex between MDM2 and a small molecule inhibitor. J Biomol NMR. 2004; 30(2):163-73. DOI: 10.1023/B:JNMR.0000048856.84603.9b. View